BioSphere Medical Retains the Equity Group to Provide Investor Relations Services.ROCKLAND, Mass. -- BioSphere 1. All the regions of the earth and its atmosphere in which living organisms are found or can live. 2. The living organisms and their environment composing the biosphere. bi  o·spher Medical, Inc. (NASDAQ: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids 1. having a fibrous structure; resembling a fibroma. 2. fibroma. 3. leiomyoma. 4. in the plural, a colloquial term for leiomyoma of the uterus. fi·broid (f, hypervascularized tumors and vascular malformations today announced that it has retained The Equity Group Inc. to provide investor relations services to the Company. Richard Faleschini, President and Chief Executive Officer of BioSphere Medical, noted, "A growing number of physicians and patients recognize Uterine Fibroid Embolization ("UFE UFE - Ufficio Federale dell'Energia UFE - Unidentified Flags and Ensigns UFE - United for a Fair Economy UFE - Unrestricted Free Agent UFE - Uterine Fibroid Embolization") as an effective alternative to hysterectomy in treating symptomatic uterine fibroids. More than 40,000 women in the United States with this condition have been successfully treated with BioSphere Medical's proprietary microsphere technology. Since coming on board at the end of 2004, our senior management team has advanced numerous initiatives to further penetrate an estimated UFE patient population of approximately 5 million in the United States. We believe that record Q1-05 and Q2-05 revenues and our continued traction in implementing local sales and market development activities evidences our growing success. At the same time, we are seeking to leverage our intellectual property to create new treatment modalities and expand our industry presence." Mr. Faleschini concluded, "As a result of the confidence we have in our business going forward, we have retained The Equity Group to help us in our efforts to communicate BioSphere Medical's accomplishments, strategy and outlook to a larger and more diverse group of investment professionals and financial media. The Equity Group came highly recommended as a respected, experienced and results-driven investor relations firm. We were impressed by the caliber, longevity, and references of their clients, and are confident that they will represent us well." The Equity Group Inc., which was founded in 1974, provides a full spectrum of investor and financial public relations services primarily to companies listed on the Nasdaq, American and New York Stock Exchanges. For more information, visit www.theequitygroup.com. About BioSphere Medical, Inc. BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Factors That May Affect Future Results" in the Company's Annual Report or Form 10-K for the period ending December 31, 2004, and Form 10-Q for the period ending June 30, 2005, as well as other filings that the Company makes with the SEC. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion